US 12,357,645 B2
Drug combination for treatment of gastric cancer
Mohana R. Velagapudi, Tampa, FL (US); and Ashok Kumar Saluja, Tampa, FL (US)
Assigned to Minneamrita Therapeutics LLC, Tampa, FL (US)
Appl. No. 18/721,770
Filed by MINNEAMRITA THERAPEUTICS LLC, Tampa, FL (US)
PCT Filed Mar. 8, 2024, PCT No. PCT/US2024/019195
§ 371(c)(1), (2) Date Jun. 19, 2024,
PCT Pub. No. WO2024/187139, PCT Pub. Date Sep. 12, 2024.
Application 18/721,770 is a continuation in part of application No. PCT/US2023/015809, filed on Mar. 21, 2023.
Claims priority of provisional application 63/489,205, filed on Mar. 9, 2023.
Prior Publication US 2024/0415856 A1, Dec. 19, 2024
Int. Cl. A61K 31/665 (2006.01); A61K 31/337 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/665 (2013.01) [A61K 31/337 (2013.01); A61P 35/00 (2018.01)] 15 Claims
 
1. A method for treating gastric cancer in a cancer patient, the method comprising administering to a gastric cancer patient during a 28 day cycle a therapeutically effective combination of:
a) about 0.25 mg to about 2.0 mg of minnelide according to a first regimen wherein a dose is given once per day on days 1 to 5, 8 to 12, and 15 to 19 of the cycle; and
b) about 60 mg/m2 to about 100 mg/m2 of paclitaxel according to a second regimen wherein a dose is given once per day on days 1, 8, and 15 of the cycle;
wherein the 28-day cycle is repeated one or more times and the combination effectively treats the gastric cancer.